Axinn Advised Thermo Fisher on $12.5B Acquisition of QIAGEN
March 3, 2020
Axinn represented Thermo Fisher Scientific Inc., the world leader in serving science, in its proposed $12.5 billion acquisition of QIAGEN N.V., a leading global provider of molecular diagnostics and sample preparation technologies. The Axinn antitrust team included partners John Harkrider, Michael Keeley, and Mark Alexander.
To subscribe to our publications, click here.
Featured Insights
Featured Insights
AHLA Health Care Transactions Program 2026
Sponsorship
Antitrust
IPWatchdog Sixth Annual Live Conference
Speaking Engagement
Intellectual Property
ABA White Collar Crime Institute 2026
Speaking Engagement
GCR Live Cartels: 2026
Speaking Engagement
Antitrust
PLI Fundamentals of Taking and Defending Depositions 2026
Speaking Engagement
Litigation & Trials
SCCE 14th Annual European Compliance & Ethics Institute
Speaking Engagement
Antitrust
California Adopts Broad Premerger Notification Requirement
Axinn Viewpoints
Antitrust
John Harkrider and Craig Minerva Win 2026 Law360 Distinguished Legal Writing Award
News
Antitrust
Noerr Competition Day 2026
Speaking Engagement
Antitrust
Axinn Adds Three Seasoned Antitrust Litigators, Reinforcing Trial Bench and West Coast Presence
News
Antitrust